Concepedia

Erik Verner

EV

Statistics

Publications

24

Citations

4.2K

H-Index

21

Active since

1992

Affiliations

Principia Biopharma (United States)(Current)

Stanford University

Pharmacyclics (United States)

Stanford Medicine

Calithera (United States)

Erik Verner is an author at Principia Biopharma (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

1992–2024

24

Publications

24

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

, , +17

Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases

John R. Somoza, R.J. Skene, B.A. Katz et al. · Structure · 2004 · 698 citations · Full text

, , +9

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Sriram Balasubramanian, Jason Ramos, Weigang Luo et al. · Leukemia · 2008 · 446 citations · Full text

, , +16

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen et al. · Nature Chemical Biology · 2015 · 430 citations · Full text

, , +14

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity <i>in vitro</i> and <i>in vivo</i>

Joseph J. Buggy, Zhe Cao, Kathryn E. Bass et al. · Molecular Cancer Therapeutics · 2006 · 125 citations · Full text

, , +12

1–5 of 24